dc.creatorRiquelme, Erick [Univ Mayor, Fac Sci, Ctr Integrat Biol, Santiago, Chile]
dc.creatorZhang, Yu; Zhang, Liangliang; Montiel, Maria; Zoltan, Michelle; Dong, Wenli; Quesada, Pompeyo; Sahin, Ismet; Chandra, Vidhi; San Lucas, Anthony; Scheet, Paul; Xu, Hanwen; Hanash, Samir M.; Feng, Lei; Burks, Jared K.; Do, Kim-Anh; Peterson, Christine B.; Nejman, Deborah; Tzeng, Ching-Wei D.; Kim, Michael P.; Sears, Cynthia L.; Ajami, Nadim; Petrosino, Joseph; Wood, Laura D.; Maitra, Anirban; Straussman, Ravid; Katz, Matthew; White, James Robert; Jenq, Robert; Wargo, Jennifer; McAllister, Florencia
dc.date.accessioned2020-04-12T14:11:55Z
dc.date.accessioned2020-04-14T15:28:49Z
dc.date.accessioned2022-10-18T18:41:09Z
dc.date.available2020-04-12T14:11:55Z
dc.date.available2020-04-14T15:28:49Z
dc.date.available2022-10-18T18:41:09Z
dc.date.created2020-04-12T14:11:55Z
dc.date.created2020-04-14T15:28:49Z
dc.date.issued2019
dc.identifierRiquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., ... & Scheet, P. (2019). Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell, 178(4), 795-806.
dc.identifier0092-8674
dc.identifier1097-4172
dc.identifierhttps://doi.org/10.1016/j.cell.2019.07.008
dc.identifierhttp://repositorio.umayor.cl/xmlui/handle/sibum/6322
dc.identifierDOI: 10.1016/j.cell.2019.07.008
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4454165
dc.description.abstractMost patients diagnosed with resected pancreatic adenocarcinoma (PDAC) survive less than 5 years, but a minor subset survives longer. Here, we dissect the role of the tumor microbiota and the immune system in influencing long-term survival. Using 16S rRNA gene sequencing, we analyzed the tumor microbiome composition in PDAC patients with short-term survival (STS) and long-term survival (LTS). We found higher alpha-diversity in the tumor microbiome of LTS patients and identified an intra-tumoral microbiome signature (Pseudoxanthomonas-Streptomyces-Saccharopolyspora-Bacillus clausii) highly predictive of long-term survivorship in both discovery and validation cohorts. Through human-into-mice fecal microbiota transplantation (FMT) experiments from STS, LTS, or control donors, we were able to differentially modulate the tumor microbiome and affect tumor growth as well as tumor immune infiltration. Our study demonstrates that PDAC microbiome composition, which cross-talks to the gut microbiome, influences the host immune response and natural history of the disease.
dc.languageen
dc.publisherCELL PRESS
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceCell, AGO, 2019. 178(4): p. 795-
dc.subjectBiochemistry & Molecular Biology; Cell Biology
dc.titleTumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución